Viral Safety Of Biologics: What's Changing With The ICH Q5A Revision?
ICH Q5A is currently being revised to address recent scientific advancements including novel therapeutic modalities, new manufacturing paradigms, updates in viral clearance applications, and alternate detection technologies. We'll discuss the expected changes and potential impact on viral safety strategies.
In this webinar, you will learn:
- The Importance of virus testing in biologics products
- Regulatory landscape, expectations for the Q5A revision
- Examples of alternate testing schedules, impact on viral clearance
VIEW THE WEBINAR! Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X
Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.
Subscribe to Biosimilar Development X
Subscribe to Biosimilar Development